Molindone
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Impulsive Aggression Comorbid With ADHD in Children
Conditions
Impulsive Aggression Comorbid With ADHD in Children
Trial Timeline
Sep 1, 2011 → Feb 1, 2013
NCT ID
NCT01416064About Molindone
Molindone is a phase 2 stage product being developed by Supernus Pharmaceuticals for Impulsive Aggression Comorbid With ADHD in Children. The current trial status is completed. This product is registered under clinical trial identifier NCT01416064. Target conditions include Impulsive Aggression Comorbid With ADHD in Children.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01416064 | Phase 2 | Completed |
Competing Products
2 competing products in Impulsive Aggression Comorbid With ADHD in Children
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SPN-810M | Supernus Pharmaceuticals | Phase 1 | 28 |
| SPN-810 + Placebo | Supernus Pharmaceuticals | Phase 2 | 47 |